Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. and Medshine Discovery Inc. have identified benzoxazinone derivatives acting as mineralocorticoid receptor (MR) antagonists reported to be useful for the treatment of diabetic nephropathy.
Glaxosmithkline Intellectual Property Ltd. has synthesized cytochrome bc1 complex (complex III) (Plasmodium falciparum) inhibitors reported to be useful for the treatment of malaria.
Celgene Corp. has disclosed sphingosine 1-phosphate receptor 5 (S1PR5; EDG8) modulators reported to be useful for the treatment of Alzheimer's disease and multiple sclerosis.
Myrtelle Inc. and Raaven Therapeutics AB have partnered on the development of novel recombinant adeno-associated virus (rAAV) vectors to advance gene therapy treatments for diseases of the central nervous system (CNS) in which myelin is affected.